CanSino Biologics Inc. (the “Company,” stock code: 6185) convened its 2025 second extraordinary general meeting (EGM) on November 27, 2025. Attendance included 132,670,900 H shares, with 35.82% in person or by proxy, and 114,372,901 A shares (excluding 406,098 repurchased shares) with 38.53% in person or by proxy. All resolutions proposed were approved by poll, including special and ordinary resolutions; two director appointments were passed via cumulative voting.

Effective November 27, 2025, the Company’s Articles of Association have been amended. The EGM also confirmed the election of two independent non-executive directors, Mr. Man Cho (左敏) and Ms. Xuefeng Ji (紀雪峰), whose terms will extend until the expiration of the third session of the Board of Directors.

Following the EGM, the Board approved adjustments to its committees, effective immediately until the current Board session ends. The Audit Committee is chaired by Mr. Yiu Leung Andy Cheung and comprises Ms. Ji and Mr. Li. The Remuneration and Assessment Committee is chaired by Mr. Cho, with Mr. Cheung, Ms. Ji, Mr. Li, and Dr. Yu serving as members. The Nomination Committee is chaired by Ms. Ji, supported by Mr. Cho and Dr. Yu.